⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
ASTERDM - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.7
| Stock Code | ASTERDM | Market Cap | 34,282 Cr. | Current Price | 662 ₹ | High / Low | 732 ₹ |
| Stock P/E | 104 | Book Value | 85.6 ₹ | Dividend Yield | 0.76 % | ROCE | 139 % |
| ROE | 200 % | Face Value | 10.0 ₹ | DMA 50 | 630 ₹ | DMA 200 | 604 ₹ |
| Chg in FII Hold | -0.26 % | Chg in DII Hold | -0.20 % | PAT Qtr | 58.9 Cr. | PAT Prev Qtr | 105 Cr. |
| RSI | 56.8 | MACD | 16.8 | Volume | 6,69,457 | Avg Vol 1Wk | 10,87,876 |
| Low price | 419 ₹ | High price | 732 ₹ | PEG Ratio | 0.34 | Debt to equity | 0.28 |
| 52w Index | 77.5 % | Qtr Profit Var | -11.7 % | EPS | 5.86 ₹ | Industry PE | 43.5 |
📊 Financials
- Revenue & Profitability: PAT declined from ₹105 Cr. to ₹58.9 Cr., showing -11.7% quarterly weakness. EPS at ₹5.86 is modest relative to valuation.
- Margins & Returns: ROCE at 139% and ROE at 200% appear unusually high, likely due to accounting adjustments or one-off factors, not sustainable operational efficiency.
- Debt & Liquidity: Debt-to-equity ratio of 0.28 indicates moderate leverage, manageable but worth monitoring.
- Cash Flow: Dividend yield of 0.76% provides limited shareholder returns.
💹 Valuation
- P/E Ratio: 104 vs Industry PE of 43.5 — trading at a steep premium.
- P/B Ratio: Current price ₹662 vs Book Value ₹85.6 — ~7.7x book value, expensive relative to assets.
- PEG Ratio: 0.34 — indicates attractive valuation relative to growth, despite high P/E.
- Intrinsic Value: Current price is above fair value, offering limited margin of safety.
🏢 Business Model & Competitive Advantage
- Operates in healthcare services with strong presence in India and GCC markets.
- Brand recognition and diversified operations provide resilience.
- High reported returns may not be sustainable; profitability needs consistency.
📈 Entry Zone & Long-Term Guidance
- Entry Zone: Attractive accumulation range between ₹630 – ₹650, near DMA 50 support.
- Long-Term Holding: Fundamentals are mixed with high valuations and profit volatility. Suitable for cautious investors seeking healthcare exposure; accumulate only on dips.
✅ Positive
- Strong brand presence in healthcare services.
- PEG ratio of 0.34 indicates attractive valuation relative to growth.
- MACD positive (16.8) reflects bullish technical momentum.
⚠️ Limitation
- Extremely high P/E ratio (104) compared to industry average (43.5).
- Quarterly PAT declined (-11.7%), showing short-term weakness.
- Dividend yield of 0.76% is modest.
📉 Company Negative News
- FII holdings declined by 0.26% and DII holdings by 0.20%, showing reduced institutional confidence.
- High leverage compared to peers (Debt-to-equity 0.28).
📈 Company Positive News
- Strong brand presence in healthcare sector.
- PEG ratio suggests growth potential despite high valuations.
- MACD positive indicates bullish technical signals.
🏭 Industry
- Healthcare sector benefits from rising demand and structural growth in India and GCC.
- Industry PE at 43.5 is much lower than company’s valuation, highlighting relative overpricing of ASTERDM.
🔎 Conclusion
ASTERDM shows mixed fundamentals with strong brand presence and growth potential but suffers from high valuations, profit volatility, and reduced institutional confidence. While healthcare demand remains favorable, the stock trades at a steep premium. Best strategy: accumulate cautiously near ₹630–₹650 and hold for long-term exposure to healthcare growth, while monitoring profitability consistency and debt levels.